Web of Science

4 downloads 0 Views 28KB Size Report
available evidence, valerian seems to be the most promising candidate for insomnia and anxiety in bipolar disorder. Conclusions: Adjunctive herbal medicines ...
Web of Science [v.5.23] - Export Transfer Service

1 of 1

http://apps.webofknowledge.com/OutboundService.do?action=go&displa...

Web of Science™ Page 1 (Records 1 -- 4) [1] Record 1 of 4 Title: Clinical applications of herbal medicines for anxiety and insomnia; targeting patients with bipolar disorder Author(s): Baek, JH (Baek, Ji Hyun); Nierenberg, AA (Nierenberg, Andrew A.); Kinrys, G (Kinrys, Gustavo) Source: AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY Volume: 48 Issue: 8 Pages: 705-715 DOI: 10.1177/0004867414539198 Published: AUG 2014 Abstract: Objectives: Patients with bipolar disorder frequently continue to experience residual anxiety and insomnia between mood episodes. In real-world practice, patients increasingly self-prescribe alternative medicines. Methods: We reviewed case reports, open-label, and placebo-controlled trials investigating the use of herbal medicines to treat anxiety and insomnia, and discussed their potential applications for bipolar disorder. Results: Eleven herbal medicines that have been studied in human subjects are included in this review. Mechanisms of action, efficacy, side effects, and drug-drug interactions are discussed. Based on currently available evidence, valerian seems to be the most promising candidate for insomnia and anxiety in bipolar disorder. Conclusions: Adjunctive herbal medicines may have the potential to alleviate these symptoms and improve the outcomes of standard treatment, despite limited evidence. Physicians need to have a more in-depth understanding of the evidence of benefits, risks, and drug interactions of alternative treatments. Accession Number: WOS:000340578900004 PubMed ID: 24947278 ISSN: 0004-8674 eISSN: 1440-1614 Record 2 of 4 Title: Utilization of herbal and nutritional compounds among older adults with bipolar disorder and with major depression Author(s): Keaton, D (Keaton, Daniel); Lamkin, N (Lamkin, Nathan); Cassidy, KA (Cassidy, Kristin A.); Meyer, WJ (Meyer, William J.); Ignacio, RV (Ignacio, Rosalinda V.); Aulakh, L (Aulakh, Lakyntiew); Blow, FC (Blow, Frederic C.); Sajatovic, M (Sajatovic, Martha) Source: INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY Volume: 24 Issue: 10 Pages: 1087-1093 DOI: 10.1002/gps.2227 Published: OCT 2009 Abstract: Objectives Herbal and nutritional compounds (HNC) are widely used among geriatric populations with depression, however little data exists on HNC use in older populations with bipolar disorder. The goal of this study was to evaluate orally-ingested HNC use in individuals with bipolar disorder and with major depression. Methods This was across-sectional analysis of self-reported factual knowledge of HNC, individual perspective on efficacy and safety of HNC, patterns of HNC use, and discussion of HNC with health care providers in 50 older adults with bipolar disorder and 50 older adults with major depression. Results In this sample, approximately 30% of older individuals with depression or bipolar disorder used orally-ingested HNC. Over 40% of older adults believed that HNC is FDA-regulated and 14-20% preferred to take HNC compared to physician-prescribed psychotropic medications. Use of HNC was more common among older adults with bipolar disorder (44%) compared to older adults with major depression (16%, p = 0.003). The majority of older adults with mood disorders (64%) had not discussed use of HNC with their treating physicians. Conclusion Orally ingested HNC was used by nearly one in three older adults with mood disorders, and was more common among those with bipolar disorder compared to those with major depression. Most individuals did not discuss HNC use with their physicians. Clinicians need to assess for HNC use, particularly with respect to potential drug-drug interactions. Copyright (C) 2009 John Wiley & Sons, Ltd. Accession Number: WOS:000270831000007 PubMed ID: 19274637 Author Identifiers:

Author

ResearcherID Number

ORCID Number

Sajatovic, Martha I-8001-2014 ISSN: 0885-6230

Record 3 of 4 Title: Adjunctive herbal medicine with carbamazepine for bipolar disorders: A double-blind, randomized, placebo-controlled study Author(s): Zhang, ZJ (Zhang, Zhang-Jin); Kang, WH (Kang, Wan-Hu); Tan, QR (Tan, Qing-Rong); Li, Q (Li, Qiang); Gao, CG (Gao, Cheng-Ge); Zhang, FG (Zhang, Feng-Gang); Wang, HH (Wang, Huai-Hai); Ma, XC (Ma, Xian-Cang); Chen, C (Chen, Ce); Wang, W (Wang, Wei); Guo, L (Guo, Li); Zhang, YH (Zhang, Ya-Hong); Yang, XB (Yang, Xiao-Bo); Yang, GD (Yang, Guang-De) Source: JOURNAL OF PSYCHIATRIC RESEARCH Volume: 41 Issue: 3-4 Pages: 360-369 DOI: 10.1016/j.jpsychires.2005.06.002 Published: APR-JUN 2007 Abstract: Chinese herbal medicines possess the therapeutic potential for mood disorders. This double-blind, randomized, placebo-controlled study was designed to evaluate the efficacy and side effects of the herbal medicine called Free and Easy Wanderer Plus (FEW?) as an adjunct to carbamazepine (CBZ) in patients with bipolar disorders. One hundred and twenty-four bipolar depressed and 111 manic patients were randomized to treatment with CBZ alone, CBZ plus FEWP, or equivalent placebo for 12 weeks. CBZ was initiated at 300 mg/day and FEWP was given at a fixed dose of 36 g/day. Efficacy measures included the Hamilton Rating Scale for Depression, Montgomery-Asberg Depression Rating Scale, Young Mania Rating Scale, Bech-Rafaelsen Mania Scale, and Clinical Global Impression-Severity (CGI-S). CBZ monotherapy produced significantly greater improvement on manic measures at week 2 through endpoint and CGI-S of depression at endpoint compared to placebo. CBZ monotherapy also yielded significantly higher clinical response rates than placebo on bipolar depression (63.8% vs. 34.8%, p = 0.044) and mania (87.8% vs. 57.1%, p = 0.0 12). Compared to CBZ monotherapy, adjunctive FEWP with CBZ resulted in significantly better outcomes on the three measures of depression at week 4 and week 8 and significantly greater clinical response rate in depressed subjects (84.8% vs. 63.8%, p = 0.032), but failed to produce significantly greater improvement on manic measures and the response rate in manic subjects. There was a lesser incidence of dizziness and fatigue in the combination therapy compared to CBZ monotherapy. These results suggest that adjunctive FEWP has additive beneficial effects in bipolar patients, particularly for those in depressive phase. (c) 2005 Elsevier Ltd. All rights reserved. Accession Number: WOS:000243214000022 PubMed ID: 16081106 ISSN: 0022-3956 Record 4 of 4 Title: Use of herbal products and symptoms of bipolar disorder Author(s): Emmanuel, NP (Emmanuel, NP); Jones, C (Jones, C); Lydiard, RB (Lydiard, RB) Source: AMERICAN JOURNAL OF PSYCHIATRY Volume: 155 Issue: 11 Pages: 1627-1627 Published: NOV 1998 Accession Number: WOS:000076786000042 PubMed ID: 9812133 ISSN: 0002-953X Web of Science™ Page 1 (Records 1 -- 4) [1]

© 2016 THOMSON REUTERS

TERMS OF USE

PRIVACY POLICY

FEEDBACK

12/27/2016 8:44 PM